Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Basal Cell 3Basal Cell Nevus Syndrome 3Pancreatic Neoplasms 2Neoplasms 2Head and Neck Neoplasms 1Chondrosarcoma 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × IPI-926 × Clear all
NCT01383538 2017-08-08

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

University of California, San Francisco

Phase 1 Completed
15 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT01130142 2017-03-06

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

Infinity Pharmaceuticals, Inc.

Phase 1/2 Completed
122 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡